Agoracom Blog Home

Posts Tagged ‘CBD’

CLIENT FEATURE: Prior Chief Medical Officer and Senior Director of Oncology Research and Development with Pfizer Inc. appointed APPB CEO $PFE $WMD.ca $CGRW $APH.ca $GBLX $ACG.ca $ACB.ca $WEED.ca $HIP.ca

Posted by AGORACOM at 11:41 AM on Monday, June 3rd, 2019
  • Dr. Raymond  W. Urbanski MD, PhD, will work closely with the Board of Directors to set the vision and strategic direction of the company
  • Will establish organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences. 
  • Overseeing the development of key products in the Applied BioSciences’ product pipeline
  • Directing development within the newly formed Applied BioPharma Division which is focused on innovative cannabinoid therapies being developed to address the unmet medical needs of patients across multiple therapeutic areas.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected] Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Link to AppliedBioSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp

CLIENT FEATURE: Bougainville Ventures $BOG.ca Turnkey Greenhouse Growing Infrastructure Provider $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 2:18 PM on Thursday, May 30th, 2019

Why Bougainville?

  • Landlord for licensed marijuana growers in the United States
  • Brilliant business plan that removes all risk and appeals to traditional real estate investors
  • Bougainville does not “touch the plant” by only providing agricultural infrastructure to tenants
  • Converts irrigated farmland to greenhouse-equipped farmland
  • Signed Second Tenant for 21,000 SQF Lease
  • Ready for occupancy
  • Room for expansion

Recent Milestones

  • Signed Sponsored Research Agreement for a CBD Energy Drink With Israeli Based R&D Company – Read More
  • Bougainville and Project 470 Acres Enter the Canadian Hemp CBD Extraction Markets – Read More
  • Acquired Interest in Five Alberta Retail Locations – Read More

Bougainville Hemp Farm Acquisition Drives It Closer To Vertical Integration

FULL DISCLOSURE: Bougainville Ventures is an advertising client of AGORA Internet Relations Corp.

INTERVIEW: Bougainville $BOG.ca Hemp Farm Acquisition Drives It Closer To Vertical Integration $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 4:54 PM on Thursday, May 23rd, 2019

When it went public in September of last year, Bougainville Ventures (BOG:CSE) started out as a cannabis real estate company, providing turnkey greenhouse solutions to tenant growers with a long-term goal of emulating the McDonald’s real estate model. That model is still at the core of BOG but company principals are using their expertise to slowly but surely create a vertically integrated powerhouse.  More than just lip service, the Company has announced the following in 2019 and we haven’t even hit June yet:

  • April 15 – Acquired an interest in 5 Alberta retail locations
  • April 25 – Binding LOI to construct a Canadian Hemp/CBD processing facility
  • May 14 – Signed A Sponsored Research Agreement With Israeli R&D Company For A CBD Energy Drink
  • May 23 – Acquired An American Hemp production and processing company to produce high-quality CBD extracts

We sat down with Bougainville Director, Richard Cindric to find out how these significant developments all tie in together as the Company races towards becoming a vertically integrated player.

CLIENT FEATURE: $APPB Prior Chief Medical Officer and Senior Director of Oncology Research and Development with Pfizer Inc. Joins APPB as its CEO $PFE $WMD.ca $CGRW $APH.ca $GBLX $ACG.ca $ACB.ca $WEED.ca $HIP.ca

Posted by AGORACOM at 11:28 AM on Thursday, May 23rd, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • Dr. Raymond  W. Urbanski MD, PhD, will work closely with the Board of Directors to set the vision and strategic direction of the company
  • Will establish organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences. 
  • Overseeing the development of key products in the Applied BioSciences’ product pipeline
  • Directing development within the newly formed Applied BioPharma Division which is focused on innovative cannabinoid therapies being developed to address the unmet medical needs of patients across multiple therapeutic areas.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Link to AppliedBioSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp

Bougainville Ventures Inc. $BOG.ca Signs Definitive Agreement with Oregon Hemp Farm $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 7:03 AM on Thursday, May 23rd, 2019
  • Further to the letter of intent with Worm Castings Farms Inc. Company signed a definitive agreement to complete the acquisition
  • Under the terms of the Worm Castings Transaction, Bougainville will provide total consideration of 10 million common shares of Bougainville at a deemed price of CAD$0.12 and a cash payment of USD$350,000 in return for 70% of Worm Castings profits.

VANCOUVER, British Columbia, May 23, 2019 — BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE: BOG) (8BV-FF:Frankfurt Stock Exchange) is pleased to announce that further to the letter of intent (“LOI”) with Worm Castings Farms Inc. (“Worm Castings”) announced in the Company news release dated October 29, 2018 the Company signed a definitive agreement to complete the acquisition of Worm Castings (“the Worm Castings Transaction”). Worm Castings is the sole owner of an Oregon State Hemp production and processing license, issued by the Oregon State Regulatory approval board, for total consideration consisting of 10 million common shares of Bougainville at a deemed price of CAD$0.12 per share and a cash payment of USD$350,000.

TERMS OF THE TRANSACTION

Under the terms of the Worm Castings Transaction, Bougainville will provide total consideration of 10 million common shares of Bougainville at a deemed price of CAD$0.12 and a cash payment of USD$350,000 in return for 70% of Worm Castings profits.

Subject to completion of the Worm Castings Transaction the board of directors of Bougainville Director’s will approve the Company to deliver the final outstanding payment of $USD120,000 to Worm Castings which will complete the USD$350,000 deposit, which will satisfy Bougainville’s obligation under the Worm Castings Transaction. Bougainville plans to invest up to USD$1,000,000 to expand the capacity of Worm Castings in agriculture, associated infrastructure, and working capital. Bougainville has secured the services of the Worm Castings founders for a period of a minimum of five years to aid with the anticipated expansion of the business in Oregon and the rest of the United States.

President & CEO, Andy Jagpal Comments: 

“This acquisition of Worm Casting is a means to further our strategy of providing large quantities of high-quality CBD extracts. The Worm Casting Transaction provides Bougainville with a vertically-integrated and licensed cultivator. In addition to having 10 acres worth of industrial hemp ready for processing, they possess a premium high quality cloned feminized hemp plants with 10-15% CBD and 0.3% THC resulting in maximized CBD oil content within each plant.”  

PRIVATE PLACEMENT FINANCING

Bougainville is also pleased to announce that it has arranged a private placement (the “Private Placement”) of units (each a “Unit”) at a price of $0.12 per Unit basis for gross proceeds of up to $500,000. Each unit is comprised of one common shares (each a “Share”) of the Company and one common share purchase warrant (each a “Warrant”). Each Warrant entitles the holder to purchase one additional common share (each “Warrant Share”) of the Company at an exercise price of $0.25 per Warrant Share for a term that is 24 months from the date of closing of the Private Placement. 

The Company wishes to correct an error in its news release dated May 1, 2019 in which the Company announced the closing of an oversubscribed private placement for which 3,166,666 Units were issued at a price of $0.06 per Unit for $190,000 in gross proceeds (the “Closed Private Placement”). The Closed Private Placement resulted in the issuance of 3,316,666 Units of the Company at a price of $0.06 per Unit for $199,000 in gross proceeds

About Bougainville Ventures, Inc.

Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 10,000 square feet of space being prepared for production in Oroville, Washington state. Bougainville possesses sufficient land for two more pods of the same size.

For more information please visit: http://bougainvilleinc.com/

On behalf of the Board of Directors

BOUGAINVILLE VENTURES INC.

_____________________

Andy Jagpal, CEO and Director

For further information, please contact the IR department at [email protected] or by phone at 1-888-395-6399.

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Bougainville $BOG.ca Signs a Sponsored Research Agreement for a CBD Energy Drink With Israeli Based R&D Company $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 12:29 PM on Tuesday, May 14th, 2019
  • Signed a Sponsored Research Agreement to develop a one of a kind water soluble cannabis-based (CBD) supplement energy drink to improve workout performance
  • Bougainville agrees to fund certain CBD-based research projects like CBD-Oils, CBD-Creams, and CBD-Supplements.

VANCOUVER, British Columbia, May 14, 2019 — Bougainville Ventures Inc. (CSE:BOG) (Frankfurt:8BV) is pleased to announced it has signed a Sponsored Research Agreement to develop a one of a kind water soluble cannabis-based (CBD) supplement energy drink to improve workout performance.

Pursuant to its agreement with an Israeli based research firm Bougainville agrees to fund certain CBD-based research projects like CBD-Oils, CBD-Creams, and CBD-Supplements. The first project will be to develop a formula, which will be a water soluble cannabis-based (CBD) supplement to boost energy and to improve workout performance.

Terms of the Agreement

Bougainville will pay a 5% Royalty from the sale, transfer or order disposition of the product, for a period of six (6) years from the completion of the product. Bougainville will have exclusive rights to commercialize the product in Canada and first right of refusal to commercialize the product in the US.

Bougainville Shall pay the Israeli based research firm $25,000 USD upon the execution of the Definitive Agreement by non-refundable check dated July 1, 2019. And an additional $50,000 USD shall be paid by Bougainville in favor of the research firm based on milestones.

Israel is at the Forefront of Medical Cannabis Research

Israel is one of the most progressive nations for medical marijuana research comes courtesy of the government’s involvement. Not only do they sponsor the majority of clinical trials, but the Israeli military has endorsed the cannabinoid THC as part of a treatment program for post-traumatic stress disorder (PTSD). In 2017 Israel saw more than 110 clinical trials take place. Their topic of study included cannabis as a treatment for Parkinson’s, multiple sclerosis (MS), Crohn’s disease and several other forms of chronic pain. Israel dominates the medical marijuana research space and the Government has plans to build one of the world’s most extensive medical cannabis research and development facilities in the world.

Andy Jagpal, President, Comments:
“We are excited to strike a relationship to develop a CBD infused energy drink as Canada’s edible marijuana market is around the corner from being fully legal within the year. We are also in contact with processors in Canada to manufacture the energy drink and with our Saskatchewan-based hemp farmers to source the CBD for our products.”

About Bougainville Ventures, Inc.  
Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost.

For more information please visit: http://bougainvilleinc.com/

On behalf of the Board of Directors 
BOUGAINVILLE VENTURES INC.

Andy Jagpal, CEO and Director

For further information, please contact Andy Jagpal at [email protected] or 1-888-395-6399

CLIENT FEATURE: North Bud Farms $NBUD.ca Sustainable Low Cost, High Quality #Cannabinoid Production and Procurement $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 11:03 AM on Monday, May 13th, 2019

North Bud Farms Signs Binding Letter of Intent to Enter U.S. Market with Strategic Acquisition of Multi-State Licensed Operator Eureka Vapor

  • Transaction valued at CAD$20 million
  • In 2018, Eureka recognized revenue of approximately CAD$11.5 million*
    • net profit margin of 16%* from its California and Colorado operations
  • Anticipates further growth in revenue due to anticipated changes to retail regulation of adult cannabis use in California.

WHY NORTHBUD FARMS?

  • Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening this year
    As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
  • Infused products sector has become the highest margin segment of the industry
  • Positioned to be a raw input producer for this space
  • Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products

Cultivation facility is progressing on schedule and on budget, video update below:

Click Image Below

FULL DISCLOSURE: NORTHBUD is an advertising client of AGORA Internet Relations Corp.

Bougainville Ventures Inc $BOG.ca – 8 incredible facts about the booming US #marijuana industry #weed $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 11:00 AM on Wednesday, May 8th, 2019

SPONSOR:  Bougainville Ventures Inc (CSE: BOG) Converting irrigated farmland to greenhouse-equipped farmland. Bougainville does not “touch the plant” and only provides agricultural infrastructure as a landlord for licensed marijuana growers. Click here for more info.
BOG:CSE
—————————————

8 incredible facts about the booming US marijuana industry

  • The US marijuana industry is worth billions of dollars, and is showing no signs of slowing down.
  • Ten US states have legalized recreational marijuana use, and 33 have legalized medicinal use.

The marijuana industry is booming in the United States.

From the $52 billion in sales the industry posted to the 76% increase in cannabis jobs this year, there are plenty of statistics to show marijuana’s startling contributions to the US economy.

Marijuana initiatives have swept through state legislatures in recent years. Recreational marijuana use is legal in 10 US states, while medicinal marijuana is legal in 33. Illinois became the most recent state to weigh the topic when Gov. JB Pritzker introduced a bill to legalize the drug on Saturday.

Now, the industry is showing no signs of slowing down.

Read on for eight interesting facts about the US marijuana industry:

The marijuana industry could soon be worth more than the GDP of 9 US states

Associated Press

Marijuana Business Factbook estimates the legal-marijuana industry’s economic impact in the US was between $20 billion and $23 billion in 2017. It estimates the economic impact could reach as high as $77 billion by 2022.

Those numbers are comparable to the GDPs of Idaho and West Virginia, which were both a tick over $77 billion in 2018, according to the Bureau of Economic Analysis. And it’s worth more than the GDP of nine states, including Delaware, Alaska, and both North and South Dakota.

Cannabis employs five times as many Americans as coal

Associated Press

New Frontier Data, a cannabis market-research and data-analysis firm, estimates that the US cannabis industry employs at least 250,000 people. And those are just the jobs that are directly involved with handling marijuana plants – others in the industry are harder to quantify, a New Frontier economist told the Associated Press.

Compare that to the size of one of the staple blue-collar industries, coal mining, which employed 52,300 in 2018.

Another study estimated the marijuana industry would grow to at least 330,000 jobs by 2022, a higher number than the 268,000 employees at US steel and iron mills.

The median marijuana salary is 10% higher than the US median salary

AP Photo/Steven Senne

The median salary in the marijuana industry salary was $58,511 in 2018, while the median salary for US workers as a whole was $52,863, according to Glassdoor data. That’s a difference of 10.7%.

Investors poured $10 billion into the North American marijuana industry in 2018

Investors poured more than $10 billion into the North American marijuana industry in 2018, according to the Associated Press. That’s twice the total amount invested in the previous three years.

And experts project that number will shoot up to $16 billion this year.

Source: https://markets.businessinsider.com/news/stocks/weed-us-marijuana-industry-facts-2019-5-1028177375#the-marijuana-industry-could-soon-be-worth-more-than-the-gdp-of-9-us-states1

Applied Biosciences $APPB Hires Former Pfizer Business Unit Chief Medical Officer as Chief Executive Officer $PFE $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM at 8:42 AM on Tuesday, May 7th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • Appointed Dr. Raymond W. Urbanski MD, PhD as its Chief Executive Officer.
  • Former business unit Chief Medical officer and senior director of oncology research and development with Pfizer Inc. (PFE)
  • Dr. Urbanski, will work closely with the Board of Directors, will set the vision and strategic direction of the company putting into place the organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences

LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) — Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid-based therapeutics company focused on the medical, biopharmaceutical testing, consumer and veterinary health industries, announced today the appointment of Dr. Raymond  W. Urbanski MD, PhD, the former business unit Chief Medical officer and senior director of oncology research and development with Pfizer Inc. (PFE), as its Chief Executive Officer. 

Dr. Urbanski, will work closely with the Board of Directors, will set the vision and strategic direction of the company putting into place the organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences.  Dr. Urbanski will also oversee the development of key products in the Applied BioSciences’ product pipeline, including assets within the newly formed Applied BioPharma division which is focused on innovative cannabinoid therapies being developed to address the unmet medical needs of patients across multiple therapeutic areas.

Dr. Urbanski joins Applied BioSciences with an impressive list of accomplishments throughout his career ranging from academic research and private practice to his work and rise within the pharmaceutical industry.  Dr. Urbanski spent eight years with Pfizer and held several positions within the company which included medical director of diversified products, senior medical director of breast cancer products, senior medical director of oncology clinical R&D, and eventually Vice President/Chief Medical Officer of the Established Products Business Unit.  In addition to his roles with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of MannKind Corp., and Senior Director of US Medical Affairs for Aventis.

He brings extensive experience in building highly effective and efficient organizations as well as experience in all phases of drug development across numerous therapeutic areas including hematology/oncology, rheumatology, neurology, cardiovascular medicine, and endocrinology/diabetes. 

“The strengthening of our executive team is a key development at an exciting time for the company enhancing our future growth trajectory,” said Scott Stevens, Founder and Chairman of the Board, “Dr. Urbanski’s big pharma and biotech expertise is well suited to develop the assets and relationships of Applied BioSciences and Applied BioPharma.  He will be instrumental in helping to guide our existing assets and Scientific Advisory board to commercial success. We are excited to have him join our team.”

“Since my days in practice I have been a believer in the cannabinoids.  I always knew that the cannabinoids could be useful agents for the treatment of a whole range of ailments and diseases.  As the science has progressed and some barriers have come down this is the ideal time and environment to make these products and drugs available.  Applied BioSciences is uniquely poised to lead these efforts. “commented Dr. Urbanski.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Empower Clinics $CBDT.ca Announces Closing of Acquisition of Sun Valley Clinics $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca $BUZZ.ca

Posted by AGORACOM-JC at 3:38 PM on Wednesday, May 1st, 2019
  • Completed the acquisition of Sun Valley Certification Clinics Holdings LLC
  • Operates a network of professional medical cannabis and pain management practices, with five clinics in Arizona, one clinic in Las Vegas, a tele-medicine platform serving California, and a fully developed franchise business model for the domestic cannabis industry
  • Will expand Empower’s multi-state operations, having a combined patient count of 165,000 patients, in Washington, Oregon, Illinois, Arizona, Nevada and California

VANCOUVER, May 1, 2019 - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (“Empower” or the “Company“) is pleased to announce that, pursuant to the terms of a membership interest purchase agreement dated April 30, 2019, it has completed the acquisition of Sun Valley Certification Clinics Holdings LLC (“Sun Valley“) from Andrea Klein and Dustin Klein (together, the “Vendors“) and a minority shareholder, through its wholly-owned subsidiary, Empower Healthcare Assets Inc. (“Empower Health“), for cash and share consideration having an aggregate value of US$3,835,000 (CAD$5,160,376), effective as of April 30, 2019 (the “Transaction“). Sun Valley operates a network of professional medical cannabis and pain management practices, with five clinics in Arizona, one clinic in Las Vegas, a tele-medicine platform serving California, and a fully developed franchise business model for the domestic cannabis industry.

In connection with the Transaction, Empower also acquired the 30% minority membership interests held by Green Global Properties Inc. (“Green Global“), a subsidiary of Aura Health Inc. (CSE: BUZZ), in three partially-owned subsidiaries of Sun Valley, operating clinics in Mesa and Phoenix, Arizona, and Las Vegas, Nevada, such that Empower now indirectly owns all of the membership interests in each of such subsidiaries (the “GG Acquisition“).

Over the past five years, Dustin and Andrea have built one of the most reputable and organized clinic networks in Arizona, developing a patient list of more than 45,000 unique patients, and have performed over 61,000 certifications to date. Sun Valley supports its patients with a dynamic dedicated team consisting of 52 staff, including 30 physicians.

“The acquisition of the Sun Valley clinic group has fundamentally changed the direction and growth prospects for Empower,” said Steven McAuley, Empower’s Chairman & CEO. “We have repositioned Empower as a vertically integrated global health and wellness company, helping consumers access products and specialized medical care for serious qualifying conditions. Having Dustin and Andrea Klein join me in leadership to rapidly expand Empower’s clinic and distribution network across the United States is a major step toward our ambitious objectives.”

“This acquisition is a testament to the hard work and dedication our team has provided to our community for the past five years and I look forward to being a valuable resource to the Company and on the board of directors,” said Dustin Klein, Sun Valley Co-founder.

Andrea Klein, Sun Valley Co-founder, stated, “I am delighted with our acquisition by Empower Clinics! It is the evolution of our dream, to positively affect the lives of patients across the country, and to become an adaptive and strategic organization that can harness the phenomenal and exciting growth of the cannabis industry. Steve’s vision for Empower is inspiring, and I am eager to bring our team together with his vision and grow into a dominating national brand that leads the way in patient care, employee satisfaction, and potential shareholder profitability!”

The Transaction is expected to create one of the largest clinic groups in the medical cannabis sector in the United States, which, together with Empower’s existing medical cannabis clinics, will expand Empower’s multi-state operations, having a combined patient count of 165,000 patients, in Washington, Oregon, Illinois, Arizona, Nevada and California, and the potential to rapidly expand the clinic network via the Sun Valley franchise program.

TRANSACTION HIGHLIGHTS

  • Improved Capital Markets Profile Empower is diversifying its business model to become a vertically integrated operator in the global cannabis sector with a focus on patient care, CBD product distribution, research & development and CBD product extraction. The Company believes this will appeal to a broader base of shareholders and investors and provide greater access to capital and improved trading liquidity.

  • Increased Patient Access With a rapidly expanding company-owned clinic network and significant expansion opportunity through the Sun Valley franchise model, Empower anticipates it will grow its total patient list substantially in the years ahead. This is expected to provide greater opportunity for treatment analysis using artificial intelligence (AI), validating the Company as a leader in understanding the efficacy of cannabis-related therapies.

  • Focus on CBD Product Sales Empower’s patient base and customers are expected to benefit from access to high margin derivative products, including CBD lotion, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet elixir hemp extract drops. Patients and customers will be able to access Empower’s customer service, home delivery and e-commerce platform.

  • Market Leading Technology Empower utilizes a market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care. The Company supports remote patients using its tele-medicine portal, enabling patients who do not live near one of its clinic locations, or are disabled or unable to come to a location, to still benefit from a doctor consultation.

  • The Sun Valley Clinic Locations

4218 W Dunlap Ave, Phoenix, AZ
12801 W Bell Rd #145, Surprise, AZ
4015 E Bell Rd #130, Phoenix, AZ
2011 E University Dr, Mesa, AZ
7074 E Speedway Blvd, Tucson, AZ
2550 S Rainbow Blvd, Las Vegas, NV

In connection with the closing of the Transaction (the “Closing“), Empower: (i) paid the Vendors an aggregate cash payment of US$775,000 (CAD$1,042,840), of which US$150,000 (CAD$201,840) is being heldback by Empower, half of which is to be released six months from the date of Closing and the other half of which is to be release twelve months from the date of Closing and (ii) issued the Vendors an aggregate of 22,058,823 common shares in the capital of the Company (each a “Share“) at a deemed price of US$0.136 (CAD$0.183) per Share, representing the average daily closing price of the Shares on the Canadian Securities Exchange for the 10-day trading period ended April 26, 2019. 14,705,882 of the Shares will be held in escrow by Odyssey Trust Company pursuant to an escrow agreement dated April 30, 2019, and will vest in quarterly installments over 36 months from the date of the Closing. The Company also paid US$12,318 (CAD$16,575) and issued 350,602 Shares to a minority shareholder of one of the Sun Valley subsidiaries in order to acquire her minority interest therein.

Each of the Vendors have also entered into employment agreements with an affiliate of the Company pursuant to which Dustin Klein will serve as the Vice President of Business Development, and Andrea Klein will serve as the Vice President of Operations. In these roles, they will continue to provide their extensive industry knowledge and expertise to Sun Valley and the Company. In addition, Dustin Klein has been appointed as a director of the Company, effective as of the Closing.

In consideration for the GG Acquisition, Empower Health issued Green Global a promissory note in the principal amount of US$125,000, which bears interest at the rate of 4.0% per annum and has a maturity date of July 31, 2019.

None of the Shares to be issued in connection with the Transaction will be registered under the United States Securities Act of 1933, as amended (the “1933 Act“), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons” (as such term is defined in Regulation S under the 1933 Act), absent registration or an applicable exemption from such registration requirements.

ABOUT EMPOWER

Empower is a leading multi-state operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative physician recommended treatment options. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based products in its clinics, online and at major retailers. With over 165,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the direction and growth prospects of the Company, the expansion of the company’s clinic and distribution network, the expected effect of the Vendors in their new roles with the Company, the effect on the lives of patients, the growth into a national brand, the effect of the Transaction, the diversification of the Company’s business model, the potential appeal to shareholders, the growth of the Company’s patient list and the effect thereof, the expected benefits for the company’s patient base and customers, the release of the cash consideration, the release of Shares being held in escrow in connection with the Transaction and statements regarding the Company’s proprietary product line “Sollievo”. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Company may not be able to expand, that the Transaction may not have the expected results, and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/01/c3033.html

Investors: Steve Low, Boom Capital Markets, 647-620-5101; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-6274; Investors: Steven McAuley, CEO, [email protected], 604-789-2146Copyright CNW Group 2019